- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- Reports: Bill to extend federal regulations for compounding pharmacies expected to pass House, Senate
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Helping independents compete in specialty pharmacy, Cardinal Health launches new suite of services at RBC 2013
NEW YORK - Surprise inspections at 40 compounding pharmacies in Massachusetts last fall have led to 10 being ordered to stop sterile compounding, according to published reports.
State health authorities sent cease-and-desist letters to 11 pharmacies, telling 10 to stop compounding altogether and one to stop compounding the drug sildenafil citrate. Twenty-one other pharmacies were allowed to continue compounding, but were cited for minor violations.
The inspections followed a nationwide outbreak of fungal meningitis linked to an injectable steroid drug prepared at the New England Compounding Center in Framingham, Mass. As of Monday, the outbreak had led to 696 cases of meningitis and 45 deaths in 20 states.